Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-01-31 08:57 am Unchanged | 2022-12-31 | 13G | Surface Oncology, Inc. SURF | Atlas Venture Fund IX L.P. | 2,945,453 4.870% | 0 (Unchanged) | Filing History |
| 2022-01-25 11:32 am Unchanged | 2021-12-31 | 13G | Cogent Biosciences, Inc. COGT | Atlas Venture Fund IX L.P. | 916,196 2.300% | 0 (Unchanged) | Filing History |
| 2022-01-25 11:30 am Unchanged | 2021-12-31 | 13G | Surface Oncology, Inc. SURF | Atlas Venture Fund IX L.P. | 2,945,453 6.380% | 0 (Unchanged) | Filing History |
| 2022-01-25 11:28 am Unchanged | 2021-12-31 | 13G | Spero Therapeutics, Inc. SPRO | Atlas Venture Fund IX L.P. | 1,376,968 4.260% | 0 (Unchanged) | Filing History |
| 2021-02-02 1:03 pm Sale | 2020-12-31 | 13G | Surface Oncology, Inc. SURF | Atlas Venture Fund IX L.P. | 2,945,453 7.240% | -1,709,000 (-36.72%) | Filing History |
| 2021-02-02 1:02 pm Unchanged | 2020-12-31 | 13G | Spero Therapeutics, Inc. SPRO | Atlas Venture Fund IX L.P. | 1,376,968 5.060% | 0 (Unchanged) | Filing History |
| 2021-02-02 1:02 pm Purchase | 2020-12-31 | 13G | Cogent Biosciences, Inc. COGT | Atlas Venture Fund IX L.P. | 916,196 8.080% | 916,196 (New Position) | Filing History |
| 2020-12-28 07:39 am Purchase | 2020-12-16 | 13D | Skillz Inc. SKLZ | Atlas Venture Fund IX L.P. | 1,164,220 8.000% | 1,164,220 (New Position) | Filing History |